Why new Alzheimer’s drugs are in for a tepid launch

Last week’s on-time opening of a government portal for collecting real-world evidence on Alzheimer’s drugs may have surprised some. But the timely roll-out has done little to staunch criticism of a requirement that patients and their doctors need to be part of the registry to qualify for Medicare coverage.